The effect of topical corticosteroids in combination with alefacept on circulating T‐cell subsets in psoriasis

Langewouters, A.M.G.; Bovenschen, Jorn H.; Jong, E.M.G.J. de; Erp, P.E.J. van; Kerkhof, P.C.M. van de

doi:10.1080/09546630701395044

Cited by 13 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Economidou et al found increased baseline CD3+CD25+ T cells and a reduction in CD25 expression after treatment with cyclosporine [17]. Similarly, Langewouters et al demonstrated a significant decrease in CD4+CD25+ T cells soon after the introduction of treatment with afefacept [18]. Reddy et al evaluated the expression of some subtypes of T cells before and during therapy with ustekinumab and found no impact of this therapy on the levels of circulating lymphocytes expressing CD25 [19].…”

Section: Discussionmentioning

confidence: 99%

The Expression of Activation Markers CD25 and CD69 Increases during Biologic Treatment of Psoriasis

Adamczyk,

Bartosińska,

Raczkiewicz

et al. 2023

JCM

View full text Add to dashboard Cite

CD (cluster of differentiation) 69 and CD25 are considered early and late markers of the activation of lymphocytes, respectively. CD25 is a part of the IL-2 receptor and is present on the surface of immune and non-immune cells, with high amounts on activated lymphocytes and regulatory T cells. CD69 is expressed on various types of white blood cells, including newly activated lymphocytes, lymphocytes infiltrating tissues isolated from subjects with chronic auto-inflammatory diseases, several subtypes of memory T cells and regulatory T cells. Primarily, CD69 was considered to be an early marker of the activation of lymphocytes, but, right now, data derived from in vitro and in vivo studies have revealed the immunomodulatory role of this surface antigen. In 84 patients with psoriasis, of whom 28 were treated with different biologic drugs, as well as in 29 healthy control subjects, the expression of CD25 and CD69 on different subtypes of peripheral blood mononuclear cells (PBMCs) was studied with the use of flow cytometry. Significantly higher levels of CD3/CD69-, CD8/CD69- and CD19/CD69-positive PBMCs as well as within CD3+ cells were present in subjects suffering from psoriasis when compared to healthy controls. In patients with psoriasis who were treated with biologic drugs, the levels of CD3/CD69-, CD4/CD69- and CD19/CD69-positive PBMCs, and CD3/CD69 within CD3+ cells, CD4/CD69 within CD4+ cells, CD4/CD25 within CD4+ cells and CD19/CD69 within CD19+ cells were significantly higher than before therapy. Our results support a role for activation markers, especially CD69, in psoriasis. Further research is warranted to fully clarify their significance in this common dermatosis, especially during biologic treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

The Expression of Activation Markers CD25 and CD69 Increases during Biologic Treatment of Psoriasis

Adamczyk,

Bartosińska,

Raczkiewicz

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…Moreover, we detected CLA expressing human CD8+ T cells in the peripheral blood of the huPBL-SCID-huSkin model. The presence of CLA-expressing CD8+ T cells in the peripheral blood of psoriasis patients is a hallmark of the disease [56], [57]. Most of the huPBMC-induced changes were significantly inhibited or completely prevented after CsA and Rapamycin treatment.…”

Section: Discussionmentioning

confidence: 99%

Humanized Mouse Model of Skin Inflammation Is Characterized by Disturbed Keratinocyte Differentiation and Influx of IL-17A Producing T Cells

et al. 2012

Self Cite

View full text Add to dashboard Cite

Humanized mouse models offer a challenging possibility to study human cell function in vivo. In the huPBL-SCID-huSkin allograft model human skin is transplanted onto immunodeficient mice and allowed to heal. Thereafter allogeneic human peripheral blood mononuclear cells are infused intra peritoneally to induce T cell mediated inflammation and microvessel destruction of the human skin. This model has great potential for in vivo study of human immune cells in (skin) inflammatory processes and for preclinical screening of systemically administered immunomodulating agents. Here we studied the inflammatory skin response of human keratinocytes and human T cells and the concomitant systemic human T cell response.As new findings in the inflamed human skin of the huPBL-SCID-huSkin model we here identified: 1. Parameters of dermal pathology that enable precise quantification of the local skin inflammatory response exemplified by acanthosis, increased expression of human β-defensin-2, Elafin, K16, Ki67 and reduced expression of K10 by microscopy and immunohistochemistry. 2. Induction of human cytokines and chemokines using quantitative real-time PCR. 3. Influx of inflammation associated IL-17A-producing human CD4+ and CD8+ T cells as well as immunoregulatory CD4+Foxp3+ cells using immunohistochemistry and -fluorescence, suggesting that active immune regulation is taking place locally in the inflamed skin. 4. Systemic responses that revealed activated and proliferating human CD4+ and CD8+ T cells that acquired homing marker expression of CD62L and CLA. Finally, we demonstrated the value of the newly identified parameters by showing significant changes upon systemic treatment with the T cell inhibitory agents cyclosporine-A and rapamycin.In summary, here we equipped the huPBL-SCID-huSkin humanized mouse model with relevant tools not only to quantify the inflammatory dermal response, but also to monitor the peripheral immune status. This combined approach will gain our understanding of the dermal immunopathology in humans and benefit the development of novel therapeutics for controlling inflammatory skin diseases.

show abstract

“…Betamethasone dipropionate is a potent topical corticosteroid. In the skin, it is metabolized to its active metabolite, betamethasone (Langewouters, Bovenschen, De jong, Van Erp, & Van De Kerkhof, ; Samtani, Lohle, Grant, Nathanielsz, & Jusko, ), and betamethasone will exert anti‐inflammatory, anti‐itching, anti‐allergic and vasoconstrictive actions for a long time (Barnes, ; Barnes, ). Therefore, betamethasone dipropionate is commonly used in the treatment of psoriasis and corticosteroid‐responsive dermatoses.…”

Section: Introductionmentioning

confidence: 99%

Development of a simple method for simultaneous determination of tazarotene and betamethasone dipropionate and their metabolites using LC–MS method and its application to dermatopharmacokinetic study

Zhang

Ma²,

Qian

2019

Biomedical Chromatography

View full text Add to dashboard Cite

In our study, a method for the determination for tazarotene and betamethasone dipropionate in human tissue-engineered skin was established. Tazarotene gel, betamethasone dipropionate cream or a combination cream was administered to the skin. Then the skin was taken off at 0. 25, 0.75, 1.75, 3, 5, 8, 12, 24, 36, 48 h time points after the residual drug was removed. The concentrations of tazarotene, betamethasone dipropionate and their major metabolites in skin were determined by LC-MS. Tazarotene and tazarotenic acid were detected in the concentration range of 2-200 μg/mL with an LLOQ of 2 μg/mL. Betamethasone dipropionate was detected in the concentration range 0.5-300 μg/mL with an LLOQ of 0.5 μg/mL, and betamethasone was detected at 2-200 μg/mL with an LLOQ of 2 μg/mL.The intra-and inter-day precisions of the four analytes in the skin homogenate were all <15% (RSD, %). The results showed that tazarotene could be metabolized to tazarotenic acid and betamethasone dipropionate could be metabolized to betamethasone in tissue-engineered skin. The results also revealed that this method was suitable for the simultaneous determination of tazarotene, betamethasone dipropionate and their metabolites in tissue-engineered skin.

show abstract

The effect of topical corticosteroids in combination with alefacept on circulating T‐cell subsets in psoriasis

Cited by 13 publications

References 15 publications

The Expression of Activation Markers CD25 and CD69 Increases during Biologic Treatment of Psoriasis

The Expression of Activation Markers CD25 and CD69 Increases during Biologic Treatment of Psoriasis

Humanized Mouse Model of Skin Inflammation Is Characterized by Disturbed Keratinocyte Differentiation and Influx of IL-17A Producing T Cells

Development of a simple method for simultaneous determination of tazarotene and betamethasone dipropionate and their metabolites using LC–MS method and its application to dermatopharmacokinetic study

Contact Info

Product

Resources

About